Please login to the form below

Not currently logged in

Gaucher disease

This page shows the latest Gaucher disease news and features for those working in and with pharma, biotech and healthcare.

Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal

Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal

Prevail’s pipeline spans clinical-stage and preclinical neuroscience assets, including lead gene therapies PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD) ... It has also been granted

Latest news

More from news
Approximately 5 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme and approved by the FDA in August this year. ... BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Spotlight interview: 15 minutes on patient-centricity in pharma

    Another example was a project we did for Gaucher disease type 1. ... This project involved training nurses on patient activation. The nurses felt they lacked the in-depth connection with their Gaucher disease patients so were unable to make the most of

  • emotive adds to medical team with new Scientific Lead and Associate Medical Writer

    in rare diseases such as Gaucher disease and Cushing’s disease and in hepatitis C. She also has experience in cardiovascular disease, haematology and infectious diseases. ... emotive is an award-winning healthcare communications agency working

  • Making good practice common practice in rare disease

    2016 – Researchers found that people with Gaucher disease ascribed more importance to fatigue than to other disease parameters, while their doctors put greater weight on objective measures of visceral and hematologic ... symptoms. Literature suggests

  • Focus on Rare Diseases

    As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond. ... Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease,

  • Can rare diseases be a viable option for the pharma industry?

    An example of this would be Gaucher’s disease, which has 3 specific sub-types of patients requiring dynamic modeling of the data from patient registries over a 60 year time ... Epiomic Patient Segmentation Database, Metabolic Disorders Category,

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....